CMPX vs. CTMX
CMPX (Compass Therapeutics Inc.) and CTMX (CytomX Therapeutics, Inc.) are both stocks. Both operate in the Biotechnology industry within the Healthcare sector. Over the past 5 years, CMPX returned -17.21%/yr vs -13.81%/yr for CTMX. At a 0.20 correlation, their price movements are largely independent.
Performance
CMPX vs. CTMX - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, CMPX achieves a -60.89% return, which is significantly lower than CTMX's -24.41% return.
CMPX
- 1D
- 0.96%
- 1M
- 8.25%
- YTD
- -60.89%
- 6M
- -60.23%
- 1Y
- -1.87%
- 3Y*
- -10.66%
- 5Y*
- -17.21%
- 10Y*
- —
CTMX
- 1D
- 1.90%
- 1M
- -22.97%
- YTD
- -24.41%
- 6M
- -19.50%
- 1Y
- 21.51%
- 3Y*
- 23.01%
- 5Y*
- -13.81%
- 10Y*
- -11.44%
CMPX vs. CTMX - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
CMPX Compass Therapeutics Inc. | -60.89% | 270.34% | -7.05% | -68.99% | 58.68% | -62.71% |
CTMX CytomX Therapeutics, Inc. | -24.41% | 313.59% | -33.55% | -3.13% | -63.05% | -48.33% |
Correlation
The correlation between CMPX and CTMX is 0.23, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.23 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.25 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.21 |
Correlation (All Time) Calculated using the full available price history since Apr 6, 2021 | 0.20 |
Fundamentals
CMPX:
$391.44M
CTMX:
$570.82M
CMPX:
-$0.42
CTMX:
-$0.37
CMPX:
2.10
CTMX:
1.78
CMPX:
$0.00
CTMX:
$35.54M
CMPX:
-$370.00K
CTMX:
$24.77M
CMPX:
-$72.86M
CTMX:
-$62.07M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
CMPX vs. CTMX — Risk / Return Rank
CMPX
CTMX
CMPX vs. CTMX - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Compass Therapeutics Inc. (CMPX) and CytomX Therapeutics, Inc. (CTMX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| CMPX | CTMX | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -0.24 | ||
| Sortino ratioReturn per unit of downside risk | -0.32 | ||
| Omega ratioGain probability vs. loss probability | 1.15 | 1.14 | +0.01 |
| Calmar ratioReturn relative to maximum drawdown | -0.03 | 0.41 | -0.43 |
| Martin ratioReturn relative to average drawdown | -0.07 | 0.91 | -0.98 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading charts...
Sharpe Ratios by Period
| CMPX | CTMX | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | -0.02 | 0.22 | -0.24 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | -0.20 | -0.10 | -0.10 |
Sharpe Ratio (10Y)Calculated over the trailing 10-year period | — | -0.10 | — |
Sharpe Ratio (All Time)Calculated using the full available price history | -0.27 | -0.11 | -0.16 |
Drawdowns
CMPX vs. CTMX - Drawdown Comparison
The maximum CMPX drawdown since its inception was -90.91%, smaller than the maximum CTMX drawdown of -98.74%. Use the drawdown chart below to compare losses from any high point for CMPX and CTMX.
Loading charts...
Drawdown Indicators
| CMPX | CTMX | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -90.91% | -98.74% | +7.83% |
Max Drawdown (1Y)Largest decline over 1 year | -75.04% | -53.19% | -21.85% |
Max Drawdown (3Y)Largest decline over 3 years | -76.47% | -91.59% | +15.12% |
Max Drawdown (5Y)Largest decline over 5 years | -85.53% | -94.16% | +8.63% |
Max Drawdown (10Y)Largest decline over 10 years | — | -98.74% | — |
Current DrawdownCurrent decline from peak | -76.14% | -90.59% | +14.45% |
Average DrawdownAverage peak-to-trough decline | -65.74% | -70.69% | +4.95% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 25.45% | 23.71% | +1.74% |
Volatility
CMPX vs. CTMX - Volatility Comparison
Compass Therapeutics Inc. (CMPX) has a higher volatility of 19.17% compared to CytomX Therapeutics, Inc. (CTMX) at 13.80%. This indicates that CMPX's price experiences larger fluctuations and is considered to be riskier than CTMX based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| CMPX | CTMX | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 19.17% | 13.80% | +5.37% |
Volatility (6M)Calculated over the trailing 6-month period | 112.72% | 68.42% | +44.30% |
Volatility (1Y)Calculated over the trailing 1-year period | 94.04% | 96.69% | -2.65% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 87.05% | 141.79% | -54.74% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 88.40% | 111.36% | -22.96% |
Dividends
CMPX vs. CTMX - Dividend Comparison
Neither CMPX nor CTMX has paid dividends to shareholders.
Financials
CMPX vs. CTMX - Financials Comparison
This section allows you to compare key financial metrics between Compass Therapeutics Inc. and CytomX Therapeutics, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
Frequently Asked Questions
CMPX and CTMX have a correlation of 0.23, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
CMPX has higher volatility (19.17%) compared to CTMX (13.80%). In terms of maximum drawdown, CMPX dropped -90.91% vs CTMX's -98.74%.
CTMX currently has the higher Sharpe Ratio (0.22 vs -0.02), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for CMPX and CTMX
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer